|
Multiple Studies Reinforce Clinical Utility of Oncotype
REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced results from multiple studies reinforcing the clinical utility of the company's Oncotype DX(R), a multi-gene expression test to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. This research was presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-15.
full article: http://money.cnn.com/news/newsfeeds/...17122007-1.htm
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
|